Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.0K
Source And Potency Of Stem Cells01:27

Source And Potency Of Stem Cells

6.5K
Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...
6.5K
Production of Formed Elements01:34

Production of Formed Elements

5.2K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
5.2K
Lineage Commitment01:21

Lineage Commitment

4.5K
Commitment is the  process whereby stem cells:
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Science translational medicine·2026
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.

Cell stem cell·2026
Same author

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

Leukemia·2026
Same author

Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.

British journal of haematology·2025
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Myeloproliferative neoplasm stem cells.

Adam J Mead1, Ann Mullally2

  • 1Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine and NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom; and.

Blood
|February 5, 2017
PubMed
Summary
This summary is machine-generated.

Myeloproliferative neoplasms (MPNs) originate from mutated hematopoietic stem cells (HSCs). Current therapies targeting JAK2 do not eliminate these MPN stem cells, necessitating new treatments.

More Related Videos

Purification of Prominin-1+ Stem Cells from Postnatal Mouse Cerebellum
07:04

Purification of Prominin-1+ Stem Cells from Postnatal Mouse Cerebellum

Published on: April 12, 2020

6.3K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.1K

Related Experiment Videos

Last Updated: Mar 8, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K
Purification of Prominin-1+ Stem Cells from Postnatal Mouse Cerebellum
07:04

Purification of Prominin-1+ Stem Cells from Postnatal Mouse Cerebellum

Published on: April 12, 2020

6.3K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.1K

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myeloproliferative neoplasms (MPNs) originate from somatic mutations in hematopoietic stem cells (HSCs).
  • Mutations in JAK2, CALR, or MPL genes drive MPN development by activating MPL-JAK-STAT signaling.
  • MPN stem cells exhibit a selective advantage, sustaining malignant hematopoiesis.

Purpose of the Study:

  • To understand the molecular mechanisms driving clonal dominance of MPN stem cells.
  • To facilitate the development of targeted therapies for MPNs.

Main Methods:

  • Analysis of somatic mutations in HSCs.
  • Investigation of MPL-JAK-STAT signaling pathways.
  • Evaluation of cell-extrinsic effects on the bone marrow niche.

Main Results:

  • MPN development is driven by mutations in JAK2, CALR, or MPL in HSCs.
  • MPN stem cells expand due to intrinsic advantages and niche interactions.
  • Current JAK2 inhibitors do not effectively target MPN stem cells, limiting molecular remissions.

Conclusions:

  • Targeting MPN stem cells is crucial for achieving molecular remissions in MPN patients.
  • Further understanding of MPN stem cell biology will guide the development of novel, effective therapies.